Dual-Targeting Nanomicelles Co-Loading Sorafenib and Artesunate Combats Hepatocellular Carcinoma via the Synergistically Enhanced Ferroptosis Strategy.

Authors

Wangjing Lu, Juan Yang, Jinxia Mi, Fazhen Luo, Yufan Guo, Yihong Zhang, Xupeng Zhang, Yan Xie

Published in

Advanced healthcare materials. Pages e71875. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Hepatocellular carcinoma (HCC) remains a formidable malignancy with limited response to conventional monotherapies, largely due to its complicated pathogenesis and useful cellular defense systems. In this study, we constructed a dual-targeting polymeric micelle (S&A@TPD/HG PMs), co-delivering sorafenib (SOR), and artesunate (ART) to achieve synergistic ferroptosis-based therapy against HCC. The micelle features a hyaluronic acid (HA) shell functionalized with glycyrrhetinic acid (GA) for active dual targeting to CD44 and GA receptors overexpressed on HCC cells; while its triphenylphosphonium (TPP)-decorated inner core facilitates mitochondrial anchoring and co-conveys the drugs, enabling stepwise subcellular targeting. Compared with free drugs or single-drug-loaded micelles, S&A@TPD/HG PMs effectively induced mitochondrial damage by depleting glutathione (GSH), and downregulating GSH peroxidase 4 (GPX4) expression to disrupt the mitochondrial antioxidant defense system, elevating intracellular Fe²⁺ to increase reactive oxygen species (ROS) and lipid peroxidation (LPO) production, thereby compromising mitochondrial redox homeostasis and potentiating ferroptosis jointly. This ferroptosis-inducing activity yielded potent in vivo antitumor efficacy in Huh-7 tumor-bearing nude mice, with a tumor inhibition rate of 74.23% and minimal systemic toxicity. Collectively, the organelle-specific targeting combined with co-delivery of synergistic drug pairs represents a promising strategy for combating malignancies and provides a blueprint for the rational design of multifunctional nanosystems.

PMID:
42902458
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.